A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
Inclusion Criteria:
Dry AMD (drusen and/or geographic atrophy) in both eyes
Exclusion Criteria:
Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past twelve (12) weeks.
History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant or retinal detachment.
Any of the following underlying diseases including:
Women who are pregnant or nursing. Known serious allergies to the fluorescein dye used in angiography or to the components of the ARC1905 formulation.